The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.5% in the afternoon session after the stock ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

Cambridge: Moderna, Inc. has announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

It’s no secret that our bodies’ ability to ward off pathogens and mount strong vaccine responses weakens with age, but ...

Shares of Moderna (MRNA) are up $1.97, or 8% to $26.67 in morning trading. Published first on TheFly – the ultimate source for real-time, ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

Moderna was the only company to participate in the public procurement tender for Covid-19 vaccines, meaning that Hungarian can once again be vaccinated against coronavirus with Moderna vaccines during ...

SOURCE Authors’ analysis of customer data from CVS Health and Walgreens linked to the 100 percent Medicare Enrollment File. NOTES Statistical interaction product terms between month of vaccination and ...

Eight breakthrough technologies that are redefining how we discover drugs, deliver care, and create a more connected and ...

In addition to Evercore ISI, Moderna also received a Hold from Needham’s Joseph Stringer in a report issued yesterday. However, on the same day, J.P. Morgan maintained a Sell rating on Moderna (NASDAQ ...